Eye drug maker VivaVision feels the strain in IPO funding dash
The developer of new treatments for ocular disorders is in a race against time to secure a Hong Kong listing before its cash reserves run out Key Takeaways: Two VivaVision…
Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…
